Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 4:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Trehalose Clear all
Recruiting Phase 2 Interventional

Standardized Microbiota Transplant Therapy in Crohn's Disease

NCT06631586
View directory record Official record
Conditions
Crohn Disease
Interventions
MTP-101C, MTP-101S
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Minneapolis, Minnesota • New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Recruiting Phase 1 Interventional

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

NCT07422675
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Interventions
SER-252 (PEOZ-apomorphine), enFuse
Drug · Device
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Englewood, Colorado • Hallandale, Florida • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults

NCT01575288
View directory record Official record
Conditions
Vascular Aging
Interventions
Placebo, High-dose trehalose
Drug
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
50 Years to 79 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 4 Interventional

TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

NCT05002998
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Teprotumumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

NCT05333211
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Ortho-R/PRP
Drug
Lead sponsor
ChitogenX Inc
Industry
Eligibility
40 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

NCT06531811
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler, Monodose inhaler
Drug · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

NCT05136885
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SLS-005, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 8, 2026, 4:57 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001

NCT03126318
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
COR-001, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

NCT02859441
View directory record Official record
Conditions
Von Hippel-Lindau Syndrome
Interventions
Ranibizumab, E10030
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 8, 2026, 4:57 PM EDT
Not yet recruiting Phase 2 Interventional

DaxibotulinumtoxinA for Blepharospasm

NCT07489430
View directory record Official record
Conditions
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential, Blepharospasm
Interventions
Botulinum Neurotoxin Type A
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

NCT02592551
View directory record Official record
Conditions
Mesothelioma
Interventions
MEDI4736, Tremelimumab, no other name
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 8, 2026, 4:57 PM EDT
Recruiting Phase 2 Interventional

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

NCT05440422
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Interventions
anifrolumab, Placebo
Drug · Other
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Autophagy in Type 2 Diabetes Microvascular Dysfunction

NCT05593549
View directory record Official record
Conditions
Type 2 Diabetes, Healthy Aging
Interventions
Trehalose, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 8, 2026, 4:57 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Active, not recruiting Phase 2 Interventional

Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders

NCT06503978
View directory record Official record
Conditions
Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions
MTP-101P, Vancomycin, Miralax, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
4 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 8, 2026, 4:57 PM EDT
Recruiting Phase 4 Interventional

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

NCT06655441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
3% trehalose
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Recruiting Early Phase 1 Interventional

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

NCT06058520
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Fecal Microbiota - lyophilized, Placebo drug
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 4:57 PM EDT
Not listed Phase 2 Interventional

Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders

NCT06321796
View directory record Official record
Conditions
Pitt Hopkins Syndrome
Interventions
MTP-101P, Vancomycin, Magnesium Citrate, Antacid, Placebo MTP-101P, Placebo Vancomycin
Combination Product
Lead sponsor
Gut-Brain-Axis Therapeutics Inc.
Other
Eligibility
5 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 8, 2026, 4:57 PM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 8, 2026, 4:57 PM EDT
Terminated Phase 2Phase 3 Interventional

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

NCT05490563
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
SLS-005, Placebo
Drug
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 8, 2026, 4:57 PM EDT
Completed Phase 1 Interventional

Fecal Transplant for Ulcerative Colitis

NCT03948919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Fecal microbiota, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 89 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 8, 2026, 4:57 PM EDT